According to a new study published in the European Journal of Cancer, researchers have found that an elevated c-reactive protein level is associated with poor prognosis in treated patients with prostate cancer.
C-reactive protein is a biomarker of inflammation that has been associated with prognosis in numerous solid tumors.
For this study, researchers sought to investigate whether or not a c-reactive protein is associated with prognosis in patients with prostate cancer treated with radiation. Researchers enrolled 261 patients with prostate cancer who were treated with 3D-conformal radiotherapy and were followed for a median duration of 80 months.
Researchers determined that the optimal cut-off level for plasma c-reactive protein was 8.6mgl-1. Multivariate analyses showed that an elevated c-reactive protein level was linked with decreased cancer specific survival (HR = 4.31; 95% CI: 1.22 - 15.1; P = 0.023).
In addition, results showed an association between an elevated c-reactive protein level and decreased overall survival (HR = 3.24; 95% CI: 1.84 - 5.71; P < 0.001), and clinical disease-free survival (HR = 2.07; 95% CI: 1.02 - 4.17; P = 0.043).
The findings suggest that an elevated plasma c-reactive protein level of 8.6mgl-1 is associated with a poor prognosis, but additional studies are warranted to confirm the results.
In the present study, the authors analysed the prognostic relevance of elevated plasma CRP levels in prostate cancer patients treated with radiotherapy. In the present study, an elevated plasma CRP has been identified as a prognostic factor for poor CSS, OS and DFS in prostate cancer patients undergoing radiotherapy.